Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Introduction: There are growing concerns among European health authorities regarding
increasing prices for new cancer medicines, prices not necessarily linked to health gain and …
increasing prices for new cancer medicines, prices not necessarily linked to health gain and …
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
J Jørgensen, E Hanna, P Kefalas - … of market access & health policy, 2020 - Taylor & Francis
ABSTRACT Background: The experience of Kymriah® and Yescarta® provides real-world
examples of how health-care systems approach and manage the reimbursement of one-off …
examples of how health-care systems approach and manage the reimbursement of one-off …
Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
DT Michaeli, M Mills, P Kanavos - Applied health economics and health …, 2022 - Springer
Purpose Oncology drugs are often approved for multiple indications, for which their clinical
benefit varies. Aligning a single price to this differing value remains a challenge. This study …
benefit varies. Aligning a single price to this differing value remains a challenge. This study …
Accelerating patient access to oncology medicines with multiple indications in Europe
R Lawlor, T Wilsdon, E Darquennes… - Journal of market …, 2021 - Taylor & Francis
Background: In recent years, innovation in oncology has created new challenges for pricing
and reimbursement systems. Oncology medicines with multiple indications face a number of …
and reimbursement systems. Oncology medicines with multiple indications face a number of …
Comparing access to orphan medicinal products in Europe
Objectives The primary objective of this study was to compare the availability and access of
orphan medicinal products (OMPs) in the devolved nations in the United Kingdom (UK) …
orphan medicinal products (OMPs) in the devolved nations in the United Kingdom (UK) …
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
DT Michaeli, M Mills, T Michaeli, A Miracolo… - Investigational New …, 2022 - Springer
Background. Previous research focused on the clinical evidence supporting new cancer
drugs' initial US Food and Drug Administration (FDA) approval. However, targeted drugs are …
drugs' initial US Food and Drug Administration (FDA) approval. However, targeted drugs are …
Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries
Background New medicines are increasingly being identified as efficacious across multiple
indications. The impact of current pricing and reimbursement policies on launch decisions …
indications. The impact of current pricing and reimbursement policies on launch decisions …
Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop
NR Latimer, D Pollard, A Towse, C Henshall… - BMC Health Services …, 2021 - Springer
Background It is increasingly common for two or more treatments for cancer to be combined
as a single regimen. Determining value and appropriate payment for such regimens can be …
as a single regimen. Determining value and appropriate payment for such regimens can be …
Multi-indication pricing: nice in theory but can it work in practice?
J Mestre-Ferrandiz, N Zozaya, B Alcalá… - …, 2018 - Springer
For medicines with different valued indications (uses), multi-indication pricing implies
charging different prices for different uses. In this article, we assess how multi-indication …
charging different prices for different uses. In this article, we assess how multi-indication …
Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products: evidence from nine OECD countries
M Mills, P Kanavos - PharmacoEconomics-Open, 2023 - Springer
Background New pharmaceuticals are increasingly being developed for use across multiple
indications. Countries across Europe and North America have adopted a range of different …
indications. Countries across Europe and North America have adopted a range of different …